NCT04330040: Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 4
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients with HR+ breast cancer must have been treated with a prior endocrine therapy

Comments are closed.

Up ↑